



"CAPTURING CANCER COMPLEXITY AND CLINICAL CHALLENGES"

CCBIO1 Newsletter

DIRECTOR'S COMMENTS

EDITOR: eli.vidhammer@uib.no

Dear all

Congratulations to several CCBIO-members for receiving a significant amount of both new and renewed grants! And to some of you for more personal grants for travels and project purposes.

A special congratulations to Line Bjørge for the prestigious appointment as ESMO Faculty Member. Read the story below.

Most of the educational events and research seminars are still web-based. Thanks to all of you involved. CCBIO905 on methods in cancer biomarker research was successful with more than 110 participants. Another success was the Graphic Design Workshop in a CCBIO-EMBO collaboration. Very useful for all participants.

We recently announced the CCBIO-MASTERCLASS concept. The "class of 2020" – 10 selected junior investigators from the various teams – have already been identified. The program, which is coordinated by Yamila, was kickstarted by presenting the CCBIO-JAW module (Junior Application Writing). Two sessions have been given on how to read calls and write applications for own funding. The Masterclass program, hopefully 8 sessions during 2021, will present different strategies and tools on how to perform efficient career planning towards independency for the young talents.

Please also read about women's health initiatives and UIB's open science policy. Best of luck to Ehsan with his doctoral defense tomorrow. And thanks to Harsh (again) and Ole for accepting positions – welcome to the CCBIO family. Finally, save the many important dates for the spring of 2021, for CCBIO908, CCBIO903, BMED904, research seminars, and other events (see web calendar).

Despite the many Covid-19 challenges, time has been running quickly this fall. By the end of this special year, we are hopefully also approaching the end of the pandemic. I wish you all the best and would like to thank you for all the good work, the many initiatives, and the good ideas waiting to be activated. Be careful and stay safe – Merry Christmas and warm wishes for 2021!

Best regards, Lars A. Akslen, Director

Programs and Research Teams

Mechanisms of Tumor-Microenvironment Interactions:

- Donald Gullberg
- Karl-Henning Kalland
- Emmet McCormack

Exploration and Validation of Cancer Biomarkers:

- Lars A. Akslen
- Jim Lorens
- Camilla Krakstad
- Daniela Costea
- Elisabeth Wik

Clinical Applications and Trial Studies:

- Bjørn Tore Gjertsen
- Oddbjørn Straume
- Line Bjørge

Health Ethics, Prioritization and Economics:

- Roger Strand
- John Cairns
- Ole Frithjof Norheim

Additional resources: Bioinformatics and Big Data

- Inge Jonassen

Strategic Advice

- Rolf Reed

Centre Director:

Prof. Dr. Med Lars A. Akslen
+ 47 55 97 31 82
lars.akslen@uib.no

Administrative Leader:

Geir Olav Løken
+ 47 55 58 54 36
geir.loken@uib.no

All administrative officers: [link.](#)

FUNDING SECURED FOR SEVERAL PROJECTS

Helse Vest has now allocated their 2021 funding, and granted CCBIO support for 5 new projects and continuation of 9 ongoing projects. We are also happy to congratulate Liv Cecilie Vestrheim Thomsen with a grant from the Raagholt Foundation, and Dana Costea/Line Bjørge/Harsh Dongre with a PhD grant from NKS.

Helse Vest funding for new projects within CCBIO:

- PhD Scholarship, 3 years, 100%: **Kari Strøno Wagner-Larsen**, Advanced MRI for developing more personalized treatment strategies in uterine cervical cancer (the Krakstad group)
- Open project support (for projects that will run for several years) **Bjørn Tore Gjertsen**, Single cell immune profiling in cancer, cost in 2021; NOK 660 000
- Open project support, **Elisabeth Wik**, Hormone regulators and immune landscape in breast cancer of the young - signature biomarkers for improved diagnosis and outcome, cost in 2021; NOK 1 500 000
- Open project support, **Line Bjørge**, Rethinking Ovarian Cancer: Development of New Preclinical Tools and the Design of Innovative Multimodal Treatment Strategies, cost in 2021; NOK 1 835 000
- 12 months research stay abroad, **Camilla Krakstad**, Clinical implementation of imaging and molecular markers for Endometrial Carcinoma

The complete list of funding for new projects can [be found here](#).

Renewed funding:

- PhD Scholarship, **Cecilie Fredvik Torkildsen**, Rethinking Ovarian Cancer: Extensive BioPROFILING to Better Define Operability in Cytoreductive Surgery (the Bjørge group)
- PhD Scholarship, **Julie Andrea Dybvik**, Functional imaging for individualized treatment of uterine cancer (the Krakstad group)
- PhD Scholarship, **Kristine Eldevik Fasmer**, Functional imaging for individualized treatment of uterine cancer (the Krakstad group)
- PhD Scholarship, **Njål Lura**, Precision imaging for individualized treatment in uterine cervical cancer (the Krakstad group)
- PhD Scholarship, **Pål Tore Bentsen**, Single cell immune and signaling profiles in steroid-refractory acute graft-versus-host disease (aGVHD) (the Gjertsen group)
- PhD Scholarship, **Øystein Sefland**, Dendritic cell therapy in acute myeloid leukemia – the use of a standardized allogeneic cell line, and single cell analysis as a tool for prediction and evaluation of response (the Gjertsen group)
- Postdoc grant, **Monica Hellesøy**, Combined single cell signaling and immunological profiling to assess the effects and investigate resistance mechanisms of FLT3-targeted therapies in AML (the Gjertsen group)
- Open project support, **Camilla Krakstad**, Clinical implementation of imaging and molecular markers for Endometrial Carcinoma, cost in 2021; NOK 1 500 000
- Open project support, **Daniela Elena Costea**, Defining molecular subtypes of head and neck cancer by integrative mutational, stromal and inflammatory landscape analysis, cost in 2021; NOK 1 500 000

The complete list of renewed funding for ongoing projects can be [found here](#).



In their considerations, the regional health authorities Helse Vest places main emphasis on scientific quality and benefit (clinical relevance). Regional collaboration and distribution between disciplines and between research environments have also been important criteria, as well as the degree of user participation.

"The applications reflect the research front in several important fields, and the large and strong environments are still ranking highest, with some honorable exceptions", the Regional Health Authorities says in their general report. In many of the individual projects' discussions, 'clinical relevance for Helse Vest' has become a central theme. The committees have used as a guiding criterion that supported projects should be able to produce data of significance for patient treatment within a five-year perspective. Some projects that are very good in terms of research are therefore not nominated, because of their focus on basic medical or community medicine aspects. A discussion about this should perhaps be raised in relevant forums, and clarification may be needed in the announcements," they conclude.

The complete report can be [seen here](#).

In addition, we are happy to congratulate **Liv Cecilie Vestrheim Thomsen** with a NOK 100.000 grant from the [Olav Raagholt and Gerd Meidel Raagholt Foundation](#) to her planned research project on examining treatment-related changes in the blood of women with relapsed ovarian cancer. Therapies directed against cancer in a primary setting will frequently impact the effect of subsequent treatment lines. To map how the treatment changes circulating cancer-related cells, Thomsen and her collaborators will apply single cell analyses in the form of mass cytometry on blood samples from women with ovarian cancer participating in clinical trials focusing on this disease. The antibody panel and the analysis pipeline that will be used in the project developed by Thomsen and Kopperud in collaboration with several of the CCBIO groups, funded by CCBIO through the Helse Vest strategic research initiative 2015-2019.

Congratulations are also in order for **Dana Costea, Line Bjørge and Harsh Dongre** for a **PhD grant from Norske Kvinners Sanitetsforening (NKS)** to Pharmacist **Rammah Mustafa**, who will be working on a project testing drugs currently used for other cancers, to develop personalized therapy for vulvar cancer. See an article on the [NKS grants here](#). We hope to see Rammah in place by April 2021.

LINE BJØRGE APPOINTED AS ESMO FACULTY MEMBER

CCBIO Associate PI Professor Line Bjørge has recently been appointed as ESMO faculty member for the Gynaecological Cancers faculty group for the period 2021-2024.



EUROPEAN SOCIETY
FOR MEDICAL ONCOLOGY

[ESMO](#) is the leading professional organisation for medical oncology. With more than 25,000 members representing oncology professionals from over 160 countries worldwide, ESMO is the society of reference for oncology education and information. The ESMO Faculty is composed of ESMO members and specialists in medical oncology or related fields, to promote a multidisciplinary approach to cancer. The Faculty is committed to helping ESMO with its educational responsibilities. As a ESMO faculty member, Line will be contributing to these key activities and responsibilities:

- Presenting at congresses and educational meetings
- Reviewing clinical guidelines
- Acting as ESMO spokespersons towards external partners and the media
- Collaborating in drafting the Educational programme of the ESMO congress

Congratulations to Line with the prestigious appointment, and to ESMO with their new and excellent faculty member!



Professor Line Bjørge. Photo: Ingvild Festervoll Melien

FOCUS ON IMPROVED WOMEN'S HEALTH

Line Bjørge and her group have been well covered in this fall's issue of the Gynecologic Cancer Association's magazine Afrodite.

An article is covering the Ministry of Health and Care Services' meeting this fall on a new Official Norwegian Report (NOU-report) on improved women's health, where Line Bjørge was one of the experts invited to provide input. Her entire 3 minute talk is related in the article, pages 6 and 7.

PhD Fellow Cecilie Torkildsen is also featured in the magazine, after having given a talk on a webinar on ovarian cancer organized by the Gynecologic Cancer Association, pages 8 and 9. [Link to Afrodite](#).

AFR ODI TE

 gynkreftforeningen

INCYTE NORDIC GRANT TO STEIN-ERIK GULLAKSEN

We are happy to report that Researcher Stein-Erik Gullaksen in the Gjertsen group has received this year's Incyte [Nordic Grant for Hematological Research](#).

The grant (approx. NOK 200.000) is awarded "For a project which will characterize the interaction of leukemic (CML) and healthy blood cells, and potentially will increase our understanding of the disease biology and therapeutic mechanisms, likely identifying biomarkers of early response to therapy through single cell immune profiling."

You can read an [interview with Stein-Erik](#) in Dagens Medisin, and also in [Forskning.no](#).

Incyte Biosciences

The Incyte Nordic Grant for Hematological Research

for 2020 is presented to:

Stein-Erik Gullaksen
(University of Bergen, Norway)

For a project which will characterize the interaction of leukemic (CML) and healthy blood cells, and potentially will increase our understanding of the disease biology and therapeutic mechanisms, likely identifying biomarkers of early response to therapy through single cell immune profiling

Incyte Biosciences Nordic AB

Erik Fromm
General Manager

PANEL DEBATE ABOUT THE NEW OPEN SCIENCE POLICY

This fall, the University of Bergen launched their policy for Open Science through a seminar October 22nd. CCBIO Associate PI Camilla Krakstad contributed as one of the panelists in the seminar, with audience both in the room and through a digital channel.

UiB's [Open Science policy](#) was adopted by the University Board September 24 this year, and is based on the principle that research and research processes should be "as open as possible, as closed as necessary".

The seminar is available as [a recorded video here](#), and the [program is available here](#).



2 NEW SHORT CCBIO VIDEOS

Some of you might already have noticed these 2 new videos through the faculty's social media, and if not, take a look!

[CCBIO in a Nutshell](#)—A 1 minute synopsis of what CCBIO actually does.

[Personalized Medicine for Acute Myeloid Leukemia](#) (AML) — See Postdoc Dimitrios Kleftogiannis in the Jonassen and Akslen groups explain their use of machine learning and mathematical modeling to develop classification systems for AML with single cell resolution.



Centre for
Cancer Biomarkers

CCBIO


IN A NUTSHELL

EXCITEMENT AND INTERNATIONAL PARTICIPATION AT THE FIRST FULLY WEB-BASED CCBIO905

CCBIO's PhD course CCBIO905 Methods in Cancer Biomarker Research was for the first time run on a digital platform October 27-29, 2020. The course was well attended, 80 participants followed selected lectures for non-ECTS participation, and 34 students completed the course with ECTS credits. The participants signed in from 15 different universities and 8 different countries with the majority of students from Norway and Finland.

This was the third time [CCBIO905](#) was provided to our students and PhD candidates, and the first time the course was run as a fully digital event on the Zoom platform, allowing for an extended audience. The participants signed in from 15 different universities and 8 different countries, with the majority from Norway and Finland. The huge interest in this course reflects a need for courses addressing basic information and broad introduction to the variety of biomedical methods applied in the beginning of their career in biomarker research.

The course has a focus on the full panel of advanced and standard methods with relevance for cancer biomarkers. The thematic parts include methods ranging from basic techniques on nucleotides and proteins to more advanced approaches, as well as bioinformatics and bio-banking. New this year was an increased focus on advanced *in vitro* models, including organoid cultures, and a thorough theoretical introduction to high-dimensional single cell analyses using mass cytometry and imaging mass cytometry (IMC). Read [more here](#).




GRAPHIC DESIGN WORKSHOP IN THE INTPART PROGRAM

CCBIO joined forces with [EMBO](#) December 8 and 9 for the workshop "[Applying design principles to schematic figures](#)", as part of the CCBIO INTPART program. Freelance graphic designer Sandra Krahl gave important input on how to design the illustrations in scientific publications and other medias. Two of the participants, Ulrikke Hugaas and Lise Ingebriktsen, has below given a report of their experience with the workshop.

What is the advantage of drawing when you could just write it out?

This, and many more questions were answered in the EMBO Solutions workshop, with a Zoom-audience eager to learn. EMBO is an organization that aims to support researchers around the world at all career stages, to stimulate the exchange of scientific information and to provide help to advance the research of young scientists, by teaching professional and 'soft skills' that are critical for a successful career in science. With three colored pens and blank sheets of paper, we were challenged to unleash our inner artists and apply graphic design principles to our drawings.

Starting off with a "draw-my-life", [Sandra Krahl](#), who developed the workshop, walked us through the important elements of storytelling, fonts, colors and how elements with correct highlight and sizes can turn simple sketches into professional and precise figures. We were then able to try for ourselves through several interactive assignments. This course gave us the opportunity to connect with colleagues – much appreciated in these times of covid19 – and present our work in a fun and creative way. We saw how drawings are a simple, yet powerful, tool of communication and were introduced to a multitude of tips and tricks that will be helpful alongside writing our own scientific work. All in all: time well spent, and a workshop we would highly recommend to all scientists who wish to convey their findings in a remarkable way.



COMING CCBIO COURSES

In the coming spring term, we will run the CCBIO Research School courses CCBIO908, CCBIO903 and BMED904. CCBIO908 will be on digital platform only, CCBIO903 requires on-site participation, and BMED904 will be run as a combination.

CCBIO908—Scientific Writing and Communication Seminar

April 12-15 2021 (4 half days, from ca. 11.00)

The course is part of the CCBIO/INTPART program, where students' education and exchange is promoted through collaboration between CCBIO and the Boston based Harvard Medical School and Harvard Kennedy School.

Lecturers:

- [Christine Møller](#), an experienced lecturer in medical and scientific writing with many years of experience as assistant editor of [APMIS](#).
- [Randy Watnick](#), assistant professor at the Vascular Biology Program, Harvard Medical School.
- Media Advisor [Marion Solheim](#) will be adding a lecture on science presentation, showing how to make a presentation stick - in a good way.

We will look into topics such as Organizing your ideas and improving your manuscript, Clear writing, The Art of Scientific Story Telling, The problem statement, Titles and Abstracts, Punctuation, Making a manuscript memorable, Writing a convincing cover letter, and How to avoid death by PowerPoint.

There is something to learn for all of us! We strongly encourage students at all levels, including postdocs, to prioritize this and attend! Senior staff is also very welcome. The seminar is also open to national and international visitors, and is free of charge. Note that if the course gets fully booked (and it has every time before), participants are included based on first come, first served.

This course provides 2 ECTS. You need to be registered as a student at the University of Bergen to get the ECTS registered. **Deadline for ECTS providing registration is February 1, 2021.**

- If you are already enrolled at the University of Bergen (UiB), you register through [Studentweb](#).
- If you are *not* enrolled at the UiB but want the ECTS, you register through [Søknadsweb](#), where you simultaneously apply for UiB guest student status.
- If you don't need the ECTS registered as part of an education/degree, and just want to join the lectures for professional update, you register [through this link](#), with deadline March 1, 2021.

Elisabeth Wik is coordinating the INTPART program. Course coordinator is vandana.ardawatia@uib.no, and academic responsible Yamila Torres Cleuren. **More info:** [at this page](#).



CCBIO903 Cancer research: Ethical, economic and social aspects

**Course week 1: May 31 to June 4, 2021, and
course week 2: September 6-10, 2021.**

CCBIO903 focuses on ethical, economical and societal aspects of cancer and cancer research and aims to equip PhD candidates with tools for systematic reflection on their own and related research as well as methods for assessing the cost benefit of health measures and methods of treatment.

Researchers and clinicians in the field of cancer research and care face important dilemmas daily regarding for instance the prioritization of research questions, or the choice between treatments for a patient. These dilemmas, involving both ethical considerations and health economics, can determine upon life and death for individual patients.

The course will address difficult questions:

- How can we deal with the uncertainties in the lab, while maintaining the quality of our science?
- Which drug is more suited to a patient?
- How can medical science contribute to debates on what is good for society?
- How can economic models help guide health care resource allocation?

This is a 5 ECTS course. **Registration deadline is February 1, 2021.** If you are already enrolled at the University of Bergen (UiB), you register through [Studentweb](#). If you are *not* enrolled at the UiB, you register through [Søknadsweb](#), where you simultaneously apply for UiB guest student status.

Location will be announced (will be at the University of Bergen campus). We will continuously monitor the Corona situation and consider adaptations. However, the course concept is highly interactive and process-oriented that precludes a fully digital teaching format.

John Cairns, Roger Strand and Anne Blanchard Bremer are academic responsible for the course. Administrative coordinator is Kjetil Utvik Harkestad. **More info:** [at this page](#).



BMED904—Graduate course in Extracellular Matrix

June 07-11, 2021

The course will cover various aspects of extracellular matrix (ECM) biology. A recurring theme will be the roles of the various ECM molecules and their functions in health and disease. Note, due to the uncertainty regarding the Covid-19 situation, the course is planned to combine face-to-face "seat time" for students attending in Bergen with online presentations of all lectures and lab demonstrations. The lectures are open to all interested.

Scientific program: See the preliminary program [at this link](#).

This is a 3 ECTS course. **Registration deadline for ECTS participation is February 1, 2021.**

- If you are already enrolled at the University of Bergen (UiB), you register through [Studentweb](#).
- If you are *not* enrolled at the UiB, you register through [Søknadsweb](#), where you simultaneously apply for UiB guest student status.
- If you only want to follow the lectures of this course for **professional updates** and don't need the ECTS, please [register here](#) to get access.

Place: option of on location at the University of Bergen, Haukeland University Hospital, or through a live Zoom streaming online.

Academic responsible are [Marion Kusche-Gullberg](#) and [Donald Gullberg](#).
Administrative coordinator is [Margarethe Bittins](#).

More info: [at this page](#).




Photo: Pugazendhi Murugan Erusappan

COMING DOCTORAL DEFENSES



Ehsan Hajjar defends **Thursday December 17, 2020 at 11:15** his doctoral dissertation "Next generation leukemia diagnostics and therapy through p53 isoforms" at the University of Bergen. Place: [Digital meeting room](#)

Trial lecture earlier the same day, **Thursday December 17, 2020 at 09:15**, on the topic "Gene splicing in normal and malignant cells". Place: [Digital meeting room](#).

Ehsan has done his work at the Department of Clinical Science and CCBIO.

Main supervisor: Professor Bjørn Tore Gjertsen

Co-supervisors: Senior Researcher Vibeke Andresen and Advisor Sigrun Margrethe Hjelle

See [press release](#).

NEW FACES



Harsh Dongre is not really a new face, as he was a PhD candidate in the Costea and Bjørge groups until he completed his PhD 30.04.20 with his [doctoral work](#) "Biomarkers and preclinical models for more precise diagnosis and personalized treatment of oral and vulva carcinomas". He is however now back at CCBIO, in a postdoc position with the project "Differential mechanism of tumor-stroma inter-actions in human papilloma virus (HPV) positive and HPV negative carcinomas". Harsh will work in collaboration between several CCBIO PIs: Dana Costea, Line Bjørge, Emmet McCormack and Karl-Henning Kalland. Other collaborators are Diane Bielenberg (Boston Children's Hospital, Harvard Medical School) and Silvio Gutkind (Moores Cancer Centre, UCSD).



Ole Vidhammer Bjørnstad is a new PhD candidate in the Tumor Biology Research group, with Heidrun Vethe and Lars A. Akslen as his supervisors. Ole completed his M.Sc. from UiB in the Department of Biomedicine. His PhD project will focus on different aspects of breast cancer stem cell biology and tumor environmental interactions, with special emphasis on nerves.

We look forward to exciting work from both Harsh and Ole!

RELEVANT CALLS FOR FUNDING

Here is a list of current and relevant calls, so take a look and see if any of these are relevant for you.

The results from this year's NFR applications will be announced during week 50 and 51. Check out their site for more information on exact dates and times. ([Utlysninger \(forskningssradet.no\)](https://utlysninger.forskningssradet.no))

2021 NFR FRIPRO:

10/02/2021: [Forskerprosjekt for fornyelse](#) (4-12M, 36-72 months)*

10/02/2021: [Forskerprosjekt for unge talenter](#) (4-8M, 36-48 months)*

10/02/2021: [Treåring forskerprosjekt med internasjonal mobilitet](#) (3-3.9M, 36 months)*

17/02/2021: [Samarbeidsprosjekt for å møte utfordringer i samfunn og næringsliv](#) (24-48 months)*

*can only apply to one as PI

10/02/2021: [Stort, tverrfaglig forskerprosjekt](#) (12-25M, 48-72 months)

Can apply in addition to the ones above

Other relevant grants:

DAM stiftelse:

15/2/2021: Research 2021: [Utlysning Forskning 2021 - Stiftelsen Dam](#)

15/3/2021: Helse 2021: [Utlysning Helse vår 2021 - Stiftelsen Dam](#)

European Research Council (ERC):

09/3/2021: [Starting grant](#)

20/4/2021: [Consolidator grant](#)

31/8/2021: [Advanced grant](#)

More info and advice on grants and applications:
contact CCBIO Research Advisor [Yamila Torres Cleuren](#)



CCBIO MASTERCLASS

We have the great pleasure to introduce a new educational program: CCBIO Masterclass! During 2021, 10 selected junior researchers (postdoc/researcher level) will be trained for the next steps of their scientific careers. Much like CCBIO's work with personalized cancer treatment, we will personalize research training for these invited participants representing all CCBIO groups. Research Advisor Yamila Cleuren is coordinating the program.


Each participant will be paired with a scientific mentor (outside of their research group), who will help them navigate the difficult decisions that lie ahead. We have prepared a program that will cover the following topics: mentoring and career development, conceptualizing research projects, research project management, establishing a research group, being a good leader, establishing research collaborations and networks, and science communication. CCBIO Masterclass will start in March 2021 and run until December 2021, with approximately 8 sessions (depending on Covid-19 regulations, the format is subject to change).

We have, however, kickstarted the program in November with the launch of our very first JAW batch (**J**unior **A**pplication **W**riting): a program for researchers at an early stage in their careers (postdocs/researchers) that are getting ready to prepare applications aiming for independence. The sessions were run through a digital platform due to the lockdown, and covered different topics: identifying relevant opportunities, reading a grant call, what should a good CV look like at different career stages, and how to write a good grant proposal (among other). The participants gave great feedback, and for these junior researchers applying for their first grants as PIs, we will continue with group sessions to support their grant writing activities throughout 2021.

We look forward to great results from our Masterclass participants, and hope they in turn will inspire their team mates!

COMING CCBIO EVENTS

Make sure to save the dates in your calendar, and register when applicable. You can see all planned CCBIO events in the [CCBIO web calendar](#).



- CCBIO Seminars (run as webinars) for the spring term will be:

⇒ January 28
 ⇒ February 25
 ⇒ March 25
 ⇒ April 29
 ⇒ May 27
 ⇒ June 10

Speakers will be announced.


- February 25, CCBIO Junior Scientist Symposium, digital event.
- April 12-15, [CCBIO908 – Scientific Writing and Communication Seminar](#), digital event.
- May 18, [CCBIO Satellite Symposium](#), Solstrand
- May 19-20, [CCBIO Annual Symposium](#), Solstrand
- May 31-June 4 + September 6-10, [CCBIO903 – Cancer research: Ethical, economic and social aspects](#), on campus
- June 7-11, [BMED904 – Graduate Course in Extracellular Matrix](#), on campus + digital platform
- June 17, CCBIO Junior Scientist Symposium, (on campus if possible, digital platform otherwise)

OTHER COMING EVENTS



- From January: The **UiB medical library** offers courses in spring 2021. Courses are planned being held digitally or as a combination of on-site and online. Courses: Introduction to Endnote, Workshop in EndNote, Searching in PubMed and Embase, Introduction to systematic reviews. Find [all info here](#).

- January 21, [Cancer Crosslinks 2021](#), digital event. CCBIO's partner **Oslo Cancer Cluster** invites to their annual event Cancer Crosslinks, January 21st 2021, with the overarching theme Driving the Translation of Scientific Insights Into Clinical Practice: From "Nice to Know" to "Need to Implement". A distinguished panel of international experts will present recent progress in precision treatment and cancer immunotherapy. The event is run on a digital platform, so we can all join in from wherever we are. Just remember to register.



- January 21, BBB Seminar (see the complete [spring list here](#))
- February 10, [Fremtidens Kreftbehandling: Evaluering av Nye Metoder](#), politisk helsedebatt med kreftpasienten i fokus, arrangert av Oslo Cancer Cluster, Kreftforeningen og Legemiddelindustrien. Møtet blir sendt direkte med streaming fra Kreftforeningens Vitensenter den 10 februar 2021 kl. 14:00. Registrer deg for lenke.
- February 25-26, [International Consortium for Personalised Medicine \(ICPerMed\) Conference](#), Paris.
- March 10-12, [Science, Technology, and Society: RRI Course](#), Digital Life Norway, Selbusjøen.
- May 10-12, [From Systems Medicine towards Digital Health](#), the 8th Conference on Systems Biology of Mammalian Cells, Heidelberg, Germany.
- June 9-11, [5th conference of Digital Life Norway Research School](#), Malangen Resort (Tromsø).

PUBLICATIONS

You can find the CCBIO publications [on this pubmed link](#).
See the most recent 5 below.



Illustration: Colourbox.com

- Tadele DS, Robertson J, Crispin R, Herrera MC, Chlubnova M, Piechaczyk L, Ayuda-Durán P, Singh SK, Gedde-Dahl T, Floisand Y, Skavland J, Wesche J, **Gjertsen BT**, Enserink JM. [A cell competition-based small molecule screen identifies a novel compound that induces dual c-Myc depletion and p53 activation](#). J Biol Chem. 2020 Dec 10;jbc.RA120.015285. doi: 10.1074/jbc.RA120.015285. Online ahead of print.PMID: 33303632
- Onyango TB, **Hjelle SM**, Haaland I, Vintermyr OK, **Johannessen AC**, **Gjertsen BT**. [A Comparison of p53 Isoform Profiles and Apoptosis Induced by Camptothecin or a Herbal Khat Extract \(Catha Edulis \(Vahl\) Forssk. ex Endl.\) in Leukemic Cell Lines: Exploring Cellular Responses in Therapy Development](#). Cancers (Basel). 2020 Dec 1;12(12):E3596. doi: 10.3390/cancers12123596.PMID: 33271840. Free article.
- **Kleinmanns K**, **Fosse V**, **Bjørge L**, **McCormack E**. [The Emerging Role of CD24 in Cancer Theranostics-A Novel Target for Fluorescence Image-Guided Surgery in Ovarian Cancer and Beyond](#). J Pers Med. 2020 Nov 27;10(4):255. doi: 10.3390/jpm10040255.PMID: 33260974 Free PMC article. Review.
- Nené NR, Barrett J, Jones A, Evans I, Reisel D, Timms JF, Paprotka T, Leimbach A, Franchi D, Colombo N, **Bjørge L**, Zikan M, Cibula D, Widschwendter M. [DNA methylation signatures to predict the cervicovaginal microbiome status](#). Clin Epigenetics. 2020 Nov 23;12(1):180. doi: 10.1186/s13148-020-00966-7.PMID: 33228781 Free PMC article.
- Jules Lansu, Judith V M G Bovée, Pètra Braam.... (incl. **Nina L Jebesen**). [Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcoma: A Nonrandomized Controlled Trial](#). JAMA Oncol. 2020 Nov 12;e205865. doi: 10.1001/jamaoncol.2020.5865. Online ahead of print.

RECENT CCBIO IN THE MEDIA

Recent media appearances by CCBIO PIs and group members. For all media hits, see [CCBIO's web pages](#).



12.12.20, Khrono, "[På tide å sette av fem prosent av prosjektmidlene til datahåndtering?](#)", Inge Jonassen.

08.12.20, Dagens Medisin, "[Norskutviklet behandling med effekt i kombinasjon med cellegift](#)", Bjørn Tore Gjertsen.

08.12.20, Dagens Medisin, "[Forskning på leukemi: – En rivende utvikling](#)", Bjørn Tore Gjertsen.

06.12.20, Dagens Medisin, "[Forsker på mulig immunterapi for minimal restsykdom](#)", Bjørn Tore Gjertsen.

16.11.20, Forskning.no, "[Norsk forskning gir håp: Blodkreft-rammede kan få mindre bivirkninger](#)", Stein-Erik Gullaksen.

12.11.20, EurekAlert!, "[University of Iowa virology research helps facilitate new clinical trial for COVID-19](#)", Jim Lorens.

03.11.20, Dagens Medisin, "[Norsk forsker hedret med stipend for sin forskning på blodkreft](#)", Stein-Erik Gullaksen.

28.10.20, Incyte, "[Norsk forsker prisbelønnet for forskning på kronisk myelogen leukemi](#)", Stein-Erik Gullaksen.

26.10.20, Dagens Medisin, "[Genotyping kan gi færre bivirkninger ved kreftbehandling](#)", Tormod Karlsen Bjånes.

